1. Home
  2. GEO vs SNDX Comparison

GEO vs SNDX Comparison

Compare GEO & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geo Group Inc (The) REIT

GEO

Geo Group Inc (The) REIT

HOLD

Current Price

$15.43

Market Cap

2.2B

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.05

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEO
SNDX
Founded
1984
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
GEO
SNDX
Price
$15.43
$20.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
13
Target Price
$41.00
$80.23
AVG Volume (30 Days)
1.7M
1.2M
Earning Date
02-12-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
515.49
N/A
EPS
1.69
N/A
Revenue
$2,531,574,000.00
$111,304,000.00
Revenue This Year
$7.93
$617.40
Revenue Next Year
$15.02
$115.70
P/E Ratio
$9.29
N/A
Revenue Growth
4.43
595.65
52 Week Low
$14.27
$8.58
52 Week High
$32.09
$22.73

Technical Indicators

Market Signals
Indicator
GEO
SNDX
Relative Strength Index (RSI) 36.66 45.71
Support Level $15.42 $19.99
Resistance Level $16.57 $21.89
Average True Range (ATR) 0.71 1.07
MACD -0.24 -0.11
Stochastic Oscillator 3.85 16.18

Price Performance

Historical Comparison
GEO
SNDX

About GEO Geo Group Inc (The) REIT

The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: